Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697030 | 0.98 | CA1 (0.52) | CA1FFAR1FFAR4ACE2GPR84 | |
| SCHEMBL12295119 | 0.92 | CA1 (0.46) | CA1CA2FDPS | |
| SCHEMBL20987770 | 0.85 | CA2 (0.50) | CA1FFAR1FFAR4GPR84CA2 | |
| SCHEMBL21250716 | 0.85 | CA2 (0.50) | CA1FFAR1FFAR4GPR84CA2 | |
| SCHEMBL13963511 | 0.84 | ACE2 (0.46) | CA1FFAR1FFAR4ACE2GPR84 | |
| SCHEMBL23082924 | 0.83 | CA2 (0.53) | CA1FFAR1GPR84CA2 | |
| SCHEMBL8233988 | 0.83 | GPR84 (0.57) | FFAR1FFAR4GPR84CA2 | |
| SCHEMBL8240572 | 0.83 | GPR84 (0.57) | FFAR1FFAR4GPR84CA2 | |
| SCHEMBL9849654 | 0.82 | CA1 (0.47) | CA1FFAR1FFAR4ACE2GPR84 | |
| SCHEMBL21498730 | 0.81 | CA2 (0.56) | CA1FFAR1GPR84CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190308988-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | NIRSUM LABORATORIES, INC. | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308988-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | OPRM1, OPRK1, OPRL1 | CA1 2910/4885FFAR1 80/4885FFAR4 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.